Stockreport

Martin Pharmaceuticals Secures Exclusive Rights From Mitsubishi Tanabe Pharma for Docarpamine to Treat Decompensated Chronic Liver Disease Including Ascites [Yahoo! Finance]

MITSUBISHI CH GRP U/ADR  (MTLHY) 
NASDAQ:AMEX Investor Relations: mitsubishichem-hd.co.jp/english/ir
PDF treatment of complications arising from advanced liver disease, today announced that it has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (M [Read more]